Exploring the Potential of Enhanced Prognostic Performance of NCCN‐IPI in Diffuse Large B‐Cell Lymphoma by Integrating Tumor Microenvironment Markers: Stromal FOXC1 and Tumor pERK1/2 Expression
Open Access
- 15 October 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (19) , e70305
Abstract
Background: FOXC1 and ERK1‐2 are proteins implicated in aggressive biological behavior of various malignancies including lymphomas.Material and Methods: We investigate the additive prognostic value of stromal FOXC1 expression and tumor phosphorylated ERK1‐2 (pERK1‐2) expression to the established National Comprehensive Cancer Network International Prognostic Index (NCCN‐IPI), in 92 diffuse large B‐cell lymphoma (DLBCL) cases. Multidimensional analysis using statistics and machine learning (ML) models assessed prognostic value of established clinicopathologic variables with stromal FOXC1 and tumor pERK1‐2 expressions.Results: Both high FOXC1 stroma group and high pERK1‐2 tumor group were significantly associated with shorter progression‐free survival (PFS) and overall survival (OS) compared with low group (p = 0.015, 0.034 and p = 0.025, 0.025 each respectively). In multivariable analysis, high FOXC1 stromal expression was an independent prognostic factor of OS (p = 0.037). The addition of stromal FOXC1 and tumor pERK1‐2 to the NCCN‐IPI score significantly improved prediction of time to death compared with NCCN‐IPI score alone (Harrell's C‐index = 0.801 vs. 0.764; p = 0.030). ML models reconfirmed the addition of stromal FOXC1 expression and tumor pERK1‐2 to NCCN‐IPI score had the highest C‐index (0.952) among combinations. Stromal FOXC1 and tumor pERK1‐2 were determinants of DLBCL prognosis, whose addition significantly improved prognostic performance of the NCCN‐IPI.Keywords
Funding Information
- National Research Foundation of Korea (2022R1C1C1008833, 2022R1A2C1009939)
- Ministry of Education (2019R1A6A1A09031717)
This publication has 49 references indexed in Scilit:
- Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosisLeukemia Research, 2010
- Stromal Gene Signatures in Large-B-Cell LymphomasNew England Journal of Medicine, 2008
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- Reduced-rank hazard regression for modelling non-proportional hazardsStatistics in Medicine, 2006
- Regulation of FOXC1 Stability and Transcriptional Activity by an Epidermal Growth Factor-activated Mitogen-activated Protein Kinase Signaling CascadeJournal of Biological Chemistry, 2006
- Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancyIEEE Transactions on Pattern Analysis and Machine Intelligence, 2005
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004
- Bagging survival treesStatistics in Medicine, 2003
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993